4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
678 620 3186
https://galectintherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 12
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Joel Lewis | President, CEO & Director | 870.66k | N/D | 1970 |
Mr. Jack W. Callicutt CPA | CFO, Treasurer & Corporate Secretary | 492.62k | N/D | 1967 |
Dr. Pol F. Boudes M.D., Ph.D. | Chief Medical Officer | 720.64k | N/D | 1957 |
Robert Tritt | General Counsel | N/D | N/D | N/D |
Mr. Jeff Katstra | Head of CMC & Pharmaceutical Development | N/D | N/D | N/D |
Ms. Beth Knowles | Executive Assistant & Officer Manager | N/D | N/D | N/D |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
La calificación ISS Governance QuickScore de Galectin Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.